【摘要】 目的探讨米氮平联合利培酮治疗难治性强迫症的临床疗效及安全性。方法选取2014年10月~2015年12月我院收治的120例难治性强迫症患者作为研究对象,按随机数字表法将患者分为研究组和对照组,每组60例。研究组使用米氮平联合利培酮治疗,对照组使用米氮平治疗。比较两组患者治疗总有效率、治疗前、治疗后4周、治疗后8周耶鲁-布朗强迫量表(Y-BOCS)评分、汉密尔顿抑郁量表(HAMA-14)评分、汉密尔顿焦虑量表(HAMD-21)评分及不良反应发生情况的差异。结果研究组治疗总有效率高于对照组(P<0.05),治疗后4周、治疗后8周,两组Y-BOCS、HAMA-14、HAMD-21与治疗前比较均有显著降低(P<0.05);治疗后8周,研究组Y-BOCS评分低于对照组(P<0.05),两组不良反应发生率比较无统计学差异(P>0.05)。结论米氮平联合利培酮治疗难治性强迫症疗效显著,能降低Y-BOCS、HAMA-14、HAMD-21评分,且不良反应少,值得临床推广使用。更多还原

【Abstract】 Objective To investigate the clinical efficacy and safety of mitrazapine combined with risperidone in the treatment of patients with refractory obsessive compulsive disorder. Methods 120 patients with refractory obsessive compulsive disorder were randomly divided into research group and control group with 60 cases in each. Patients in control group were treated with mitrazapine,while patients in research group were treated with mitrazapine combined with risperidone.The total effect rate,Y-BOCS score,HAMA-14 score,HAMD-21 score before treatment and 4 weeks, 8 weeks after treatment, adverse reactions rate of two groups were compared. Results The total effect rate of research group was higher than that of control group(P < 0.05).Compared with before treatment,the Y-BOCS score,HAMA-14 score,HAMD-21 score of the two groups 4 weeks,8 weeks after treatment were significantly reduced(P < 0.05).After 8 weeks treatment,the Y-BOCS score of research group were lower than that of control group(P < 0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P > 0.05). ConclusionMitrazapine combined with risperidone treatment had exact effect for refractory obsessive compulsive disorder. It could decrease Y-BOCS score,HAMA-14 score,HAMD-21 score and adverse reactions. It’s worthy of clinical popularization and application.更多还原